ClinicalTrials.gg
TerminatedNCT00460473Updated Jul 24, 2015

A Research Study to Evaluate the Effectiveness of Dexmedetomidine in Preventing Delirium After Hip Fracture Repair Surgery

A Phase 3 interventional study of Dexmedetomidine and Placebo in Delirium, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Terminated at 30 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-24.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Prevention

Why this study was terminated
The incidence of post-operative delirium observed from interim blinded data was significantly lower than the current literature in this population.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 78 studies testing dexmedetomidine in Delirium — 16 open to participants now, 18 under way, 4 of them phase 3. Dexmedetomidine · Delirium.

Enrollment
58th of 78
52 · median 98
Started
2007
with 1 other
Phase 3
11 of 78
3 open now
Registered
3rd of 78
by date
Lead sponsor
2 of 78
Hospira, now a wholly owned subsidiary of Pfizer

Among the 78 studies testing dexmedetomidine in Delirium, this one is the 58th largest by enrollment, is one of 2 that started in 2007, is one of 11 in phase 3, and was the 3rd registered.

Delirium

933 studies on the registry are indexed under Delirium; 189 are open to participants now.

Browse Delirium studies →

Open to participants now

16 of the 78 studies testing dexmedetomidine in Delirium are open now, in 6 countries. Recruiting first, the newest first:

11 more — sign in →

By country, each count listing its studies:

All 16 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 127 Delirium studies recruiting now, 99 (78%) set no upper age limit and 8 (6%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 78 studies testing dexmedetomidine in Delirium, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of perioperative use of dexmedetomidine in the prevention of postoperative delirium in subjects undergoing surgery for fractured hip with general anesthesia.

Read the detailed description

Postoperative delirium is an acute decline in cognition and attention which is usually transient but when delirium persists it can impact cognitive function, morbidity and morality. There are no drugs that are currently approved to prevent the onset of delirium but dexmedetomidine has the potential to meet this unmet medical need. Hip fractures, unfortunately are frequent occurrences in the elderly population and the elderly are more prone to developing delirium after surgery.

Dexmedetomidine is currently approved for use for 24 hours in patients on ventilators in the ICU. Study participation will last from within 72 hours of surgery to 3 days after surgery, continue throughout surgery and up to 2 hours after surgery. Delirium will be assessed prior to surgery and for 72 hours after surgery. This assessment will consist of questions to determine memory and thought process. At discharge patient's resource utilization will be evaluated and thirty days after surgery questions will be asked regarding quality of life.

03

Conditions studied

  • Delirium

Keywords

  • Mental Health
  • Neurological Disease
  • Hip Injuries and Disorders
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adult (≥18 years old) male or female who will undergo surgery for fractured hip with general anesthesia within 72 hours of admission to hospital.
  2. If female, subject is non-lactating and is either:

    1. Not of , defined as for at least 1 year or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline and is practicing one of the following methods of : oral or parenteral contraceptives, double-barrier method, vasectomized partner, or abstinence from sexual intercourse.
  3. Subject is Physical Status I, II, III, or IV.
  4. Subject (or subject's legally authorized representative) has voluntarily signed and dated the document approved by the Institutional Review Board (IRB).

Exclusion criteria

Exclusion Criteria:

  1. Cognitive function level by (MMSE) of ≤20.
  2. Subject has a positive CAM-ICU result for delirium at Screening or Baseline.
  3. Subject requires chronic antipsychotic therapy.
  4. Subject is anticipated to require additional surgical procedures during the 72 hour Screening Period and the 3 days Follow-up Period.
  5. Subject is anticipated to require repair of pelvic fractures (eg,acetabulum).
  6. Subject has participated in a trial with any experimental drug or experimental implantable device within 30 days prior to the study drug administration, or has ever been enrolled in this study.
  7. Subject known to be in liver failure.
  8. Subject has an anticipated potential for increased intracranial pressure or an uncontrolled seizure disorder or known psychiatric illness that could confound a normal response during study assessment.
  9. Subject has received treatment with a α2-agonist or antagonist (within 14 days of study entry).
  10. Subject for whom opiates, benzodiazepines, DEX or other α2-agonists are .
  11. Subject has, per the investigator's judgment, a known or suspected physical or psychological dependence on an abused drug, other than alcohol.
  12. Subject has acute unstable angina, acute myocardial infarction, HR \<50 bpm, SBP \<90 mmHg, or third degree heart block unless the subject has a pacemaker.
  13. Subject has any condition or factor which, in the Investigator's opinion, might increase the risk to the subject.
  14. Subject is not expected to live more than 60 days.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Dexmedetomidine

    Drug: Dexmedetomidine

  • Placebo comparator
    Placebo (PBO)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who experienced any postoperative delirium up to 3 days after the end of study drug infusion

    The presence of postoperative delirium will be determined by Confusion Assessment Method for the Intensive Care Unit (CAM-ICU).

    Time frame: Twice daily (between 6:00-9:00 AM and 5:00-8:00 PM) until 3 days after the end of study drug infusion.

Secondary outcomes

  1. Duration of postoperative delirium as determined by CAM-ICU up to 3 days after end of study drug infusion

    Time frame: Twice daily (between 6:00-9:00 AM and 5:00-8:00 PM) until 3 days after the end of study drug infusion.

  2. Percentage of subjects who experienced postoperative delirium each day after end of study drug infusion

    Time frame: Twice daily (between 6:00-9:00 AM and 5:00-8:00 PM) until 3 days after the end of study drug infusion.

  3. Perioperative use of all analgesics (Fentanyl, Morphine, and oral analgesics)

    Time frame: During the intraoperative period, Post-anesthesia care unit period and the 3 days Follow-up Period.

  4. Postoperative use of Midazolam

    If RASS \>0, midazolam (MDZ) 0.5-1 mg IV will be given until RASS \<0. While in PACU during study drug infusion period, MDZ (0.5-1 mg IV) will be given if RASS \>+1 under allowed maximum dose of study drug. RASS range: * +4 Combative -Overtly combative, violent, immediate danger to staff * +3 Very agitated- Pulls or removes tubes or catheters, aggressive * +2 Agitated- Frequent non-purposeful movements, fights ventilator * +1 Restless- Anxious, but movements not aggressive or vigorous * 0 Alert and calm * -1 Drowsy - Not fully alert, but sustained awakening (eye opening, eye contact) to voice (\>10 sec) * -2 Light sedation - Briefly awakens with eye contact to voice (\<10 sec) * -3 Moderate sedation - Movement or eye opening to voice (but no eye contact) * -4 Deep sedation No response to voice, but movement or eye opening to physical stimulation * -5 Unarousable No response to voice or physical stimulation

    Time frame: During the PACU period (Approximately 2 hours)

  5. Time-to-Aldrete score of ≥9

    A score of 9-10 indicates the subject has recovered from anesthesia and is ready for discharge from the PACU.

    Time frame: Every 15±5 minutes from arrival in the PACU (Approximately 2 hours)

  6. Length of post-operative hospital stay

    Time frame: From the post operative period until subject discharged from hospital

07

Study locations

30 sites
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • LAC-USC Medical Center Los Angeles
    Los Angeles, California 90033, United States
  • Huntington Memorial Hospital
    Pasadena, California 91105, United States
  • University of Miami-Jackson Memorial Medical Center
    Miami, Florida 33101, United States
  • Southeastern Clinical Research Consultants
    Orlando, Florida 32804, United States
  • Orlando Regional Healthcare, Critical Care Medicine
    Orlando, Florida 32806, United States
  • G and G Research, Inc.
    Vero Beach, Florida 32960, United States
  • Orthopaedic Center of Vero Beach
    Vero Beach, Florida 32960, United States
  • Medical College of Georgia
    Augusta, Georgia 30912, United States
  • University of Iowa Hospitals and Clinics, Dept. of Anesthesia
    Iowa City, Iowa 52242-1053, United States
  • Outcomes Research Institute
    Louisville, Kentucky 40202, United States
  • Louisiana State University, Dept. of Orthopaedic Surgery
    Shreveport, Louisiana 71103, United States
  • Spectrum Health Blodgett Campus
    Grand Rapids, Michigan 49506-2810, United States
  • William Beaumont Hospital
    Royal Oak, Michigan 48073, United States
  • Saint Mary's Duluth Clinic Health System
    Duluth, Minnesota 55805, United States
  • Mayo Clinic College of Medicine, Dept. of Anesthesiology
    Rochester, Minnesota 55906, United States
  • University of Missouri
    Columbia, Missouri 65212, United States
  • Mount Sinai School of Medicine
    Great Neck, New York 11021, United States
  • New York University Medical Center
    New York, New York 10016, United States
  • Duke University Medical Center
    Durham, North Carolina 27705, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Ohio State University Medical Center
    Columbus, Ohio 43210, United States
  • University of Pittsburgh Medical Center, Presbyterian
    Pittsburgh, Pennsylvania 15213-2582, United States
  • University of Pittsburgh Medical Center
    Pittsburgh, Pennsylvania 15232, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Research Concepts
    Bellaire, Texas 77401, United States
  • Parkland Health and Hospital System
    Dallas, Texas 75390-9179, United States
  • University of Virginia Health Systems
    Charlottesville, Virginia 22908-0710, United States
  • University of Wisconsin Medical School, Dept. of Anesthesiology
    Madison, Wisconsin 53792, United States
  • VA Medical Center
    Milwaukee, Wisconsin 53295, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Nov 2007 and a completion of Nov 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 13, 2007
First posted
Apr 16, 2007
Start
Apr 2007
Primary completionActual
Nov 2007
CompletionActual
Nov 2007
Last update
Jul 24, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00460473
Responsible party
Sponsor
First posted
Apr 16, 2007
Start date
Apr 2007
Primary completion
Nov 2007
Completion
Nov 2007
Last update
Jul 24, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion